Oncology

Nadine Barrett, PhD, MA, MPH, discusses the role of international collaborations to advance global cancer care access.

Naoto T. Ueno, MD, PhD, FACP, discussed the role of the Hawaiʻi Cancer Consortium to advance trial and treatment efforts for patients with cancer.

The FDA also approved the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients who would benefit from the treatment.

Shirish Gadgeel, MD, discusses the promising results of the randomized phase 3 HARMONi-2/AK112-303 study comparing ivonescimab to pembrolizumab in PD-L1–positive advanced non-small cell lung cancer.

The real-world study results of ciltacabtagene autoleucel are comparable to data from the CARTITUDE-1 trial, emphasizing its efficacy and safety.

Longer-term data from the phase 3 MARIPOSA trial confirm superior outcomes of a chemotherapy-free amivantamab-vmjw plus lazertinib regimen compared to osimertinib monotherapy as first-line therapy.

The addition of high-dose vitamin D3 to standard treatment did not delay the progression of cancer compared with the standard dose of vitamin D3.

At the 2024 World Conference on Lung Cancer, Ana Baramidze, MD, PhD, presented 5-year outcomes of the trial, which investigated cemiplimab monotherapy in first-line advanced non–small cell lung cancer (NSCLC) with PD-L1 expression of 50% or greater.

Victor Ambros and Gary Ruvkun received the 2024 Nobel Prize in Physiology or Medicine for discovering microRNA and its role in gene regulation.

Treosulfan showed superior benefits to busulfan as a conditioning regimen before allogenic hematopoietic stem cell transplantation (allo-HSCT).

Patients in persistently impoverished areas were also more likely to have more aggressive tumor characteristics and receive more invasive surgeries.

The results show promise for the use of Bruton tyrosine kinase inhibitors in non-Hodgkin lymphoma treatment.

Nivolumab is the only PD-1 inhibitor to show statistically significant and clinically meaningful benefits in non-small cell lung cancer compared with chemotherapy.

The new screening test provides an easier, convenient option for patients seeking to screen themselves for colorectal cancer.

Currently, standard first-line chemotherapy with or without immunotherapy for patients with non-small-cell lung cancer (NSCLC) with HER2 mutations has limited efficacy.

Fedratinib is an orally available, small molecule inhibitor of JAK-2 approved for treatment of myelofibrosis.

Currently, VLS-1488 is being evaluated in a phase 1/2 trial (NCT05902988) in various advanced tumors, including high-grade serous ovarian cancer (HGSOC).

The designation was based on results from the DESTINY-Breast06 trial, evaluating fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo) compared with chemotherapy.

The benefits of the daratumumab-based regimen were seen in all patients, including those with high and standard cytogenic risk levels.

Patients exhibited improved disease-free progression with minimal adverse effects.

Zanubrutinib demonstrated sustained responses in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

The accelerated course was safe and effective and did not increase complications in patients with breast cancer post-mastectomy undergoing breast reconstruction.

Poorer prognosis was linked to factors such as reduced hemoglobin levels and advanced stage at diagnosis.

Brooke Peters, PharmD, BCOP, discusses a study conducted at American Oncology Network (AON) to evaluate luspatercept dosing for patients with low- to intermediate-risk myelodysplastic syndromes (MDS).

Aaron Adkisson, PharmD, discusses the importance of considering factors such as age, gender, and cardiovascular comorbidities when monitoring and managing cardiotoxic risks in patients with cancer. also emphasizing patient education on recognizing early heart failure symptoms.

These interim trial results support the ongoing phase 3 ITHACA trial.

Ashraf Badros, MBCHB, discussed new data from the AURIGA study presented at the International Myeloma Society 2024 Annual Meeting, happening September 25 through 29 in Rio de Janeiro, Brazil.

The trial is evaluating ciltacabtagene autoleucel (cilta-cel, Carvykti; Johnson & Johnson) in patients with relapsed and lenalidomide-refractory multiple myeloma.